Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

新型MicroRNA结合位点SNP和透明细胞肾细胞癌（ccRCC）的风险：病例对照研究。

卷 21, 期 3, 2021

发表于: 20 November, 2020

页: [203 - 212] 页: 10

弟呕挨: 10.2174/1568009620666201120151226

价格: $65

摘要

背景：肾细胞癌占所有成人恶性肿瘤的3％。 MicroRNA通过与参与凋亡和细胞周期控制的细胞mRNA相互作用，在各种生物学过程中表现出特定功能。最近的研究报道了VHL-HIF1α途径基因的miRNA结合位点中的单核苷酸多态性（SNP）与肾癌的发生和发展的潜在关联。 目的：本研究的目的是研究与VHL-HIF1α途径基因的miRNA结合位点相互作用性质发生改变的SNP。 方法：本研究共纳入450例经组织学和临床验证的ccRCC病例和490例对照。使用TaqMan PCR等位基因鉴别方法进行基因分型。实施Kaplan-Meier统计分析方法来分析总体患者存活率。 结果：TSC1基因的rs10491534多态性与发展成晚期ccRCC的风险显着相关。与55岁及以上的对照组相比，VHL基因中rs1642742的等位基因G在ccRCC中显着流行（OR = 1.5566； CI [1.1532-2.1019]）。来自具有AG或AA基因型个体的显性模型的结果表明，与GG携带者相比，CDCP1 rs6773576的A等位基因携带者具有更高的死亡风险（HR 3.93，95％CI 1.76-17.21，log-rank P = 0.0033）。 结论：本研究描述了VHL-HIF1α途径基因中的miRNA结合位点变异与ccRCC风险的关联，这可能会影响临床结果。

关键词: 肾细胞癌，miRNA，VHL-HIF1α途径，多态性，表观遗传学。

« Previous Next »
图形摘要

[1]
Escudier, B.; Porta, C.; Schmidinger, M.; Rioux-Leclercq, N.; Bex, A.; Khoo, V.; Gruenvald, V.; Horwich, A. ESMO Guidelines Committee. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2016, 27(Suppl. 5), v58-v68.
[http://dx.doi.org/10.1093/annonc/mdw328] [PMID: 27664262]
[2]
Vasudev, N.S.; Selby, P.J.; Banks, R.E. Renal cancer biomarkers: the promise of personalized care. BMC Med., 2012, 10, 112.
[http://dx.doi.org/10.1186/1741-7015-10-112] [PMID: 23016578]
[3]
Cairns, P. Renal cell carcinoma. Cancer Biomark., 2010, 9(1-6), 461-473.
[http://dx.doi.org/10.3233/CBM-2011-0176] [PMID: 22112490]
[4]
Baylin, S.B.; Jones, P.A. Epigenetic determinants of cancer. Cold Spring Harb. Perspect. Biol., 2016, 8(9)
[http://dx.doi.org/10.1101/cshperspect.a019505] [PMID: 27194046]
[5]
Cora’, D.; Re, A.; Caselle, M.; Bussolino, F. MicroRNA-mediated regulatory circuits: outlook and perspectives. Phys. Biol., 2017, 14(4), 045001.
[http://dx.doi.org/10.1088/1478-3975/aa6f21] [PMID: 28586314]
[6]
Expósito-Villén, A.; E Aránega, A.; Franco, D. Functional role of non-coding RNAs during epithelial-to-mesenchymal transition. Noncoding RNA, 2018, 4(2), 14.
[http://dx.doi.org/10.3390/ncrna4020014] [PMID: 29843425]
[7]
Goradel, N.H.; Mohammadi, N.; Haghi-Aminjan, H.; Farhood, B.; Negahdari, B.; Sahebkar, A. Regulation of tumor angiogenesis by microRNAs: State of the art. J. Cell. Physiol., 2019, 234(2), 1099-1110.
[http://dx.doi.org/10.1002/jcp.27051] [PMID: 30070704]
[8]
Kashyap, D.; Tuli, H.S.; Garg, V.K.; Goel, N.; Bishayee, A. Oncogenic and tumor-suppressive roles of MicroRNAs with special reference to apoptosis: molecular mechanisms and therapeutic potential. Mol. Diagn. Ther., 2018, 22(2), 179-201.
[http://dx.doi.org/10.1007/s40291-018-0316-1] [PMID: 29388067]
[9]
Li, M.; Wang, Y.; Song, Y.; Bu, R.; Yin, B.; Fei, X.; Guo, Q.; Wu, B. MicroRNAs in renal cell carcinoma: a systematic review of clinical implications (Review). Oncol. Rep., 2015, 33(4), 1571-1578.
[http://dx.doi.org/10.3892/or.2015.3799] [PMID: 25682771]
[10]
He, Y.H.; Chen, C.; Shi, Z. The biological roles and clinical implications of microRNAs in clear cell renal cell carcinoma. J. Cell. Physiol., 2018, 233(6), 4458-4465.
[http://dx.doi.org/10.1002/jcp.26347] [PMID: 29215721]
[11]
Braga, E.A.; Fridman, M.V.; Loginov, V.I.; Dmitriev, A.A.; Morozov, S.G. Molecular mechanisms in clear cell renal cell carcinoma: role of miRNAs and hypermethylated miRNA genes in crucial oncogenic pathways and processes. Front. Genet., 2019, 10, 320.
[http://dx.doi.org/10.3389/fgene.2019.00320] [PMID: 31110513]
[12]
Wei, H.; Ke, H.L.; Lin, J.; Shete, S.; Wood, C.G.; Hildebrandt, M.A. MicroRNA target site polymorphisms in the VHL-HIF1α pathway predict renal cell carcinoma risk. Mol. Carcinog., 2014, 53(1), 1-7.
[http://dx.doi.org/10.1002/mc.21917] [PMID: 22517515]
[13]
Haase, V.H. The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease. Kidney Int., 2006, 69(8), 1302-1307.
[http://dx.doi.org/10.1038/sj.ki.5000221] [PMID: 16531988]
[14]
Ding, L; Jiang, Z; Chen, Q; Qin, R; Fang, Y; Li, H. A functional variant at miR-520a binding site in PIK3CA alters susceptibility to colorectal cancer in a Chinese Han population. BioMed research international, 2015.
[http://dx.doi.org/10.1155/2015/373252]
[15]
Krishnamachary, B.; Zagzag, D.; Nagasawa, H.; Rainey, K.; Okuyama, H.; Baek, J.H.; Semenza, G.L. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res., 2006, 66(5), 2725-2731.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-3719] [PMID: 16510593]
[16]
Ogasa, M.Y.; Yazaki, K.; Utsumi, Y.; Miki, N.H.; Fukuda, K. Short-time xylem tension relaxation prevents vessel refilling and alleviates cryo-fixation artifacts in diffuse-porous Carpinus tschonoskii and Cercidiphyllum japonicum. Tree Physiol., 2019, 39(10), 1685-1695.
[http://dx.doi.org/10.1093/treephys/tpz072] [PMID: 31222295]
[17]
Gunaratnam, L.; Morley, M.; Franovic, A.; de Paulsen, N.; Mekhail, K.; Parolin, D.A.; Nakamura, E.; Lorimer, I.A.; Lee, S. Hypoxia inducible factor activates the transforming growth factor-α/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J. Biol. Chem., 2003, 278(45), 44966-44974.
[http://dx.doi.org/10.1074/jbc.M305502200] [PMID: 12944410]
[18]
Li, D.H.; Whitmore, J.B.; Guo, W.; Ji, Y. Toxicity and efficacy probability interval design for phase I adoptive cell therapy dose-finding clinical trials. Clin. Cancer Res., 2017, 23(1), 13-20.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-1125] [PMID: 27742793]
[19]
Ellinger, J.; Gevensleben, H.; Müller, S.C.; Dietrich, D. The emerging role of non-coding circulating RNA as a biomarker in renal cell carcinoma. Expert Rev. Mol. Diagn., 2016, 16(10), 1059-1065.
[http://dx.doi.org/10.1080/14737159.2016.1239531] [PMID: 27649770]
[20]
Croce, C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet., 2009, 10(10), 704-714.
[http://dx.doi.org/10.1038/nrg2634] [PMID: 19763153]
[21]
Robins, H.; Press, W.H. Human microRNAs target a functionally distinct population of genes with AT-rich 3′ UTRs. Proc. Natl. Acad. Sci. USA, 2005, 102(43), 15557-15562.
[http://dx.doi.org/10.1073/pnas.0507443102] [PMID: 16230613]
[22]
Chalupová, L.; Zako vs ka, A.; Adamcova, K. Development of a novel enzyme-linked immunosorbent assay (ELISA) for measurement of serum CTRP1: a pilot study: measurement of serum CTRP1 in healthy donors and patients with metabolic syndrome. Clin. Biochem., 2013, 46(1-2), 73-78.
[http://dx.doi.org/10.1016/j.clinbiochem.2012.09.006] [PMID: 23000311]
[23]
Horikawa, Y.; Wood, C.G.; Yang, H.; Zhao, H.; Ye, Y.; Gu, J.; Lin, J.; Habuchi, T.; Wu, X. Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin. Cancer Res., 2008, 14(23), 7956-7962.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-1199] [PMID: 19047128]
[24]
Lin, J.; Horikawa, Y.; Tamboli, P.; Clague, J.; Wood, C.G.; Wu, X. Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis, 2010, 31(10), 1805-1812.
[http://dx.doi.org/10.1093/carcin/bgq168] [PMID: 20732906]
[25]
Chow, T.F.; Youssef, Y.M.; Lianidou, E.; Romaschin, A.D.; Honey, R.J.; Stewart, R.; Pace, K.T.; Yousef, G.M. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin. Biochem., 2010, 43(1-2), 150-158.
[http://dx.doi.org/10.1016/j.clinbiochem.2009.07.020] [PMID: 19646430]
[26]
Zhong, T.; Xu, F.; Xu, J.; Liu, L.; Chen, Y. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss. Biomed. Pharmacother., 2015, 69, 317-325.
[http://dx.doi.org/10.1016/j.biopha.2014.12.022] [PMID: 25661377]
[27]
Liu, H.; Gao, F.; Dahlstrom, K.R.; Li, G.; Sturgis, E.M.; Zevallos, J.P.; Wei, Q.; Liu, Z. A variant at a potentially functional microRNA-binding site in BRIP1 was associated with risk of squamous cell carcinoma of the head and neck. Tumour Biol., 2016, 37(6), 8057-8066.
[http://dx.doi.org/10.1007/s13277-015-4682-6] [PMID: 26711789]
[28]
van Houwelingen, K.P.; van Dijk, B.A.; Hulsbergen-van de Kaa, C.A.; Schouten, L.J.; Gorissen, H.J.; Schalken, J.A.; van den Brandt, P.A.; Oosterwijk, E. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer, 2005, 5, 57.
[http://dx.doi.org/10.1186/1471-2407-5-57] [PMID: 15932632]
[29]
Groulx, I.; Lee, S. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol. Cell. Biol., 2002, 22(15), 5319-5336.
[http://dx.doi.org/10.1128/MCB.22.15.5319-5336.2002] [PMID: 12101228]
[30]
Rathmell, W.K.; Chen, S. VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev. Anticancer Ther., 2008, 8(1), 63-73.
[http://dx.doi.org/10.1586/14737140.8.1.63] [PMID: 18095884]
[31]
Mehta, M.S.; Vazquez, A.; Kulkarni, D.A.; Kerrigan, J.E.; Atwal, G.; Metsugi, S.; Toppmeyer, D.L.; Levine, A.J.; Hirshfield, K.M. Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes. Breast Cancer Res. Treat., 2011, 125(3), 861-868.
[http://dx.doi.org/10.1007/s10549-010-1062-1] [PMID: 20658316]
[32]
Hildebrandt, M.A.; Lippman, S.M.; Etzel, C.J.; Kim, E.; Lee, J.J.; Khuri, F.R.; Spitz, M.R.; Lotan, R.; Hong, W.K.; Wu, X. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin. Cancer Res., 2012, 18(13), 3705-3713.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-3271] [PMID: 22577058]
[33]
Song, P.; Wang, W.; Tao, G.; Chu, H.; Wang, M.; Wu, D.; Tong, N.; Gong, W.; Zhou, J.; Zhang, Z.; Wang, B.; Zhu, H.; Zhao, Q. A miR-29c binding site genetic variant in the 3′-untranslated region of LAMTOR3 gene is associated with gastric cancer risk. Biomed. Pharmacother., 2015, 69, 70-75.
[http://dx.doi.org/10.1016/j.biopha.2014.11.008] [PMID: 25661340]
[34]
Ohlsson, C.; Wallaschofski, H.; Lunetta, K.L.; Stolk, L.; Perry, J.R.; Koster, A.; Petersen, A-K.; Eriksson, J.; Lehtimäki, T.; Huhtaniemi, I.T.; Hammond, G.L.; Maggio, M.; Coviello, A.D.; Ferrucci, L.; Heier, M.; Hofman, A.; Holliday, K.L.; Jansson, J.O.; Kähönen, M.; Karasik, D.; Karlsson, M.K.; Kiel, D.P.; Liu, Y.; Ljunggren, O.; Lorentzon, M.; Lyytikäinen, L.P.; Meitinger, T.; Mellström, D.; Melzer, D.; Miljkovic, I.; Nauck, M.; Nilsson, M.; Penninx, B.; Pye, S.R.; Vasan, R.S.; Reincke, M.; Rivadeneira, F.; Tajar, A.; Teumer, A.; Uitterlinden, A.G.; Ulloor, J.; Viikari, J.; Völker, U.; Völzke, H.; Wichmann, H.E.; Wu, T.S.; Zhuang, W.V.; Ziv, E.; Wu, F.C.; Raitakari, O.; Eriksson, A.; Bidlingmaier, M.; Harris, T.B.; Murray, A.; de Jong, F.H.; Murabito, J.M.; Bhasin, S.; Vandenput, L.; Haring, R. EMAS Study Group. Genetic determinants of serum testosterone concentrations in men. PLoS Genet., 2011, 7(10)
[http://dx.doi.org/10.1371/journal.pgen.1002313] [PMID: 21998597]
[35]
Wang, W-C.; Tsou, M-H.; Chen, H-J.; Hsu, W-F.; Lai, Y-C. Two single nucleotide polymorphisms in the von Hippel-Lindau tumor suppressor gene in Taiwanese with renal cell carcinoma. BMC Res. Notes, 2014, 7, 638.
[http://dx.doi.org/10.1186/1756-0500-7-638] [PMID: 25217002]
[36]
Znaor, A.; Lortet-Tieulent, J.; Laversanne, M.; Jemal, A.; Bray, F. International variations and trends in renal cell carcinoma incidence and mortality. Eur. Urol., 2015, 67(3), 519-530.
[http://dx.doi.org/10.1016/j.eururo.2014.10.002] [PMID: 25449206]
[37]
He, Y.; Wu, A.C.; Harrington, B.S.; Davies, C.M.; Wallace, S.J.; Adams, M.N.; Palmer, J.S.; Roche, D.K.; Hollier, B.G.; Westbrook, T.F.; Hamidi, H.; Konecny, G.E.; Winterhoff, B.; Chetty, N.P.; Crandon, A.J.; Oliveira, N.B.; Shannon, C.M.; Tinker, A.V.; Gilks, C.B.; Coward, J.I.; Lumley, J.W.; Perrin, L.C.; Armes, J.E.; Hooper, J.D. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance. Oncogene, 2016, 35(4), 468-478.
[http://dx.doi.org/10.1038/onc.2015.101] [PMID: 25893298]
[38]
Razorenova, O.V.; Finger, E.C.; Colavitti, R.; Chernikova, S.B.; Boiko, A.D.; Chan, C.K.; Krieg, A.; Bedogni, B.; LaGory, E.; Weissman, I.L.; Broome-Powell, M.; Giaccia, A.J. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKCδ-driven migration. Proc. Natl. Acad. Sci. USA, 2011, 108(5), 1931-1936.
[http://dx.doi.org/10.1073/pnas.1011777108] [PMID: 21233420]
[39]
Jeys, L.M.; Grimer, R.J.; Carter, S.R.; Tillman, R.M.; Abudu, A. Post operative infection and increased survival in osteosarcoma patients: are they associated? Ann. Surg. Oncol., 2007, 14(10), 2887-2895.
[http://dx.doi.org/10.1245/s10434-007-9483-8] [PMID: 17653803]
[40]
Emerling, B.M.; Benes, C.H.; Poulogiannis, G.; Bell, E.L.; Courtney, K.; Liu, H.; Choo-Wing, R.; Bellinger, G.; Tsukazawa, K.S.; Brown, V.; Signoretti, S.; Soltoff, S.P.; Cantley, L.C. Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients. Proc. Natl. Acad. Sci. USA, 2013, 110(9), 3483-3488.
[http://dx.doi.org/10.1073/pnas.1222435110] [PMID: 23378636]
[41]
Chou, C-T.; Li, Y-J.; Chang, C-C.; Yang, C-N.; Li, P-S.; Jeng, Y-M.; Chen, S-T.; Kuo, M-L.; Lin, I-C.; Lin, B-R. Prognostic significance of CDCP1 expression in colorectal cancer and effect of its inhibition on invasion and migration. Ann. Surg. Oncol., 2015, 22(13), 4335-4343.
[http://dx.doi.org/10.1245/s10434-015-4505-4] [PMID: 25820997]
[42]
Greene, C.J.; Attwood, K.; Sharma, N.J.; Gross, K.W.; Smith, G.J.; Xu, B.; Kauffman, E.C. Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients. Oncotarget, 2017, 8(63), 107052-107075.
[http://dx.doi.org/10.18632/oncotarget.22323] [PMID: 29291011]
[43]
Qian, W.; Kong, X.; Zhang, T.; Wang, D.; Song, J.; Li, Y.; Li, X.; Geng, H.; Min, J.; Kong, Q.; Liu, J.; Liu, Z.; Wang, D.; Zhang, Z.; Yu, D.; Zhong, C. Cigarette smoke stimulates the stemness of renal cancer stem cells via Sonic Hedgehog pathway. Oncogenesis, 2018, 7(3), 24.
[http://dx.doi.org/10.1038/s41389-018-0029-7] [PMID: 29540668]
[44]
Hunt, J.D.; van der Hel, O.L.; McMillan, G.P.; Boffetta, P.; Brennan, P. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int. J. Cancer, 2005, 114(1), 101-108.
[http://dx.doi.org/10.1002/ijc.20618] [PMID: 15523697]

Rights & Permissions Print Cite
Article Metrics
36
© 2025 Bentham Science Publishers | Privacy Policy